DIABETIC KETOACIDOSIS TREATMENT MARKET ANALYSIS

Diabetic Ketoacidosis (DKA) is a serious complication in diabetes. The condition develops when the body does not produce enough insulin. Insulin helps glucose to enter the cells and tissues, thus without insulin the body breaks down fats as fuel and this leads to production of acid in bloodstream called ketones. If the process extends for a longer duration it results in total chemical equilibrium imbalance and create life threating situation. Diabetic Ketoacidosis is most commonly associated in type 1 diabetes and type 2 diabetes patients who are also at risk to some extent Treatment of diabetic ketoacidosis involves intravenous fluid replacement, intravenous insulin and rapid electrolyte replenishment.

Global Diabetic Ketoacidosis Treatment Market: Drivers

The rising prevalence of diabetes and diabetic ketoacidosis is a major global concern. According to the U.S National Library of Health, the frequency of diabetic ketoacidosis in adults with type1 diabetes is high, and approximately one third of the adults has severe conditions such as diabetes type-1 and diabetic ketoacidosis. Moreover, healthcare providers are focused on spreading awareness regarding diabetes type 1 and diabetic ketoacidosis. For instance, in April 2020, Diabetes UK, a healthcare and research charity association in England, stated that the National Health Services should be kept open for emergency conditions such diabetic ketoacidosis as they may lead to life threating situation.

Global Diabetic Ketoacidosis Treatment Market: Impact of COVID-19

There is a two-directional relationship between diabetes and COVID-19. According to the Lancet, diabetes is associated with high risk of COVID-19 infection and secondly people with diabetes who have infected with COVID-19 need higher dose of insulin to avoid severe condition such as diabetic ketoacidosis. Moreover, healthcare professionals are facing several challenges in terms of managing patients in intensive care unit undergoing treatment of diabetic ketoacidosis. This is owing to the increasing burden on ICUs for treating critical cases of COVID-19. These factors are expected to hamper the growth of global diabetic ketoacidosis treatment market.

Global Diabetic Ketoacidosis Treatment Market: Restraints

Intravenous administration of insulin allows sugar to enter the cells which can cause blood sugar levels to drop and lead to hypoglycaemia. However, adjusting blood sugar level quickly with help of fluids and insulin can produce swelling in brain. Administration of fluids and insulin can also cause a drop in potassium level in the blood and impair activities of the heart, muscles and nervous system. These factors are expected to restrain growth of the global diabetic ketoacidosis treatment market.

Global Diabetic Ketoacidosis Treatment Market: Regional Analysis

On the basis of region, the global diabetic ketoacidosis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The rising prevalence of common chronic conditions such as diabetes and associated complications such as diabetes ketoacidosis are major burden in North America. According to the Centres for Disease Control and Prevention, till 2015, around 30 million people in the U.S. had diabetes and recorded significant increase in annual average rate of 6.3% from 2009 to 2014 of persons hospitalized due to diabetes ketoacidosis. Thus, pharmaceutical companies are focusing on direct treatment or increasing the availability of supportive treatment for diabetes ketoacidosis. For instance, in June 2020, Lexicon Pharmaceutical Inc. announced use of Zynquista (sotagliflozin) to balance the risk of diabetes ketoacidosis in adults with type-1 diabetes at the Virtual 80^th American Diabetic Association scientific session.

Moreover, there is high incidence of diabetes in Europe due to increasing fast food consumption and changing lifestyle. According to the International Diabetes Federation incidence rate of diabetes in Europe was 77% up until 2019.  In this region, intravenous insulin and electrolyte fluids are highly used treatments for diabetic ketoacidosis. In 2018, the European Journal of Internal Medicine stated that basal insulin with regular insulin fusion is well effective and a primary in treatment for diabetic ketoacidosis. Thus higher use of insulin in diabetic treatment is expected to drive growth of the European diabetic treatment market during the forecast period.

Global Diabetic Ketoacidosis Treatment Market: Competitive analysis.

Key operating players in the global diabetic ketoacidosis treatment market are Novo Nordisk A/S, Sanofi S.A, Biocon Limited, Tonghua Dongbao Pharmaceutical Co., Ltd, Oramed Pharmaceuticals Inc., Merck & Co., Inc., Pfizer Inc., Wockhardt Ltd, Eli Lilly and Company, GlaxoSmithKline plc, and Bristol Myers Squibb.

Key Developments-

1. In August 2020, Eli Lilly and Company (United States) added two non-branded insulin products Humalog mix 75/25 kwikpen and Humalog Junior kwikpen at a cost effective range to make treatment of type-1 diabetes and its complications such as diabetes ketoacidosis more affordable.
2. In 2019, Medtronic, a medical device company in Ireland, merged with Nova Nordisk, a pharmaceutical company in Denmark. The aim of this partnership is to develop solutions for diabetes and diabetic ketoacidosis by combining insulin dosage data from future Novo Nordisk and smart insulin pens by Medtronic’s Continuous Glucose Monitoring (CGM) devices.

Global Diabetic Ketoacidosis Treatment Market: Taxonomy

• By Treatment Type:
  • Electrolyte Replacement
  • Fluid Replacement
  • Insulin Therapy
• By Application:
  • Adults
  • Pediatric
• By End User:
  • Hospital
  • Ambulatory Care Centre
  • Speciality Clinics
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa